AstraZeneca: Coronary Disease trials

The registry lists 18 Coronary Disease studies with AstraZeneca as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 2 2Phase 3 6Phase 4 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial InfarctionCompletedNCT04610892Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart DiseaseCompletedNCT03351738Phase 2Results posted
• Ticagrelor China Pharmacokinetic/Pharmacodynamic StudyCompletedNCT02064985Phase 4Results posted
• Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)CompletedNCT01294462Phase 3Results posted
• 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With EzetimibeCompletedNCT00525824Phase 3Results posted
• Centralised Pan-Algerian Survey on the Undertreatment of HypercholesterolemiaCompletedNCT01768403
• A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese PatientWithdrawnNCT01757262Phase 3
• Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take StatinsCompletedNCT01047176
• Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)CompletedNCT00660764
• Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb HypercholesterolemiaCompletedNCT00654407Phase 3
• Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 WeeksCompletedNCT00653588Phase 3
• Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mgCompletedNCT00653445Phase 3
• Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)CompletedNCT00574782
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536965
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536796
• Diabetic Under 70 (Diabetics Below 70)CompletedNCT00516204
• Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)CompletedNCT00396110
• Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart DiseaseCompletedNCT00235950Phase 4